dabigatran
E245168
Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
All labels observed (3)
| Label | Occurrences |
|---|---|
| Pradaxa | 1 |
| dabigatran canonical | 1 |
| dabigatran etexilate | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2190692 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: dabigatran Context triple: [Xarelto, isComparedWith, dabigatran]
-
A.
apixaban
Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
-
B.
Xarelto
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
-
C.
warfarin
Warfarin is a long-established oral anticoagulant used to prevent and treat blood clots, requiring regular blood monitoring and dose adjustments due to its narrow therapeutic range and numerous drug and food interactions.
-
D.
Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: dabigatran Target entity description: Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
-
A.
apixaban
Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
-
B.
Xarelto
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
-
C.
warfarin
Warfarin is a long-established oral anticoagulant used to prevent and treat blood clots, requiring regular blood monitoring and dose adjustments due to its narrow therapeutic range and numerous drug and food interactions.
-
D.
Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
anticoagulant drug
ⓘ
direct thrombin inhibitor ⓘ oral anticoagulant ⓘ |
| belongsTo | Boehringer Ingelheim product portfolio ⓘ |
| hasApprovalYear | 2010 (United States) ⓘ |
| hasATCCode | B01AE07 ⓘ |
| hasBioavailability | approximately 6 percent ⓘ |
| hasBlackBoxWarning |
increased risk of thrombotic events after premature discontinuation
ⓘ
risk of spinal or epidural hematoma with neuraxial anesthesia or spinal puncture ⓘ |
| hasBrandName |
dabigatran
self-linksurface differs
ⓘ
surface form:
Pradaxa
|
| hasClinicalTrial | RE-LY trial ⓘ |
| hasCommonAdverseEffect |
bleeding
ⓘ
dyspepsia ⓘ gastritis-like symptoms ⓘ gastrointestinal bleeding ⓘ |
| hasContraindication |
active pathological bleeding
ⓘ
mechanical prosthetic heart valves ⓘ severe hypersensitivity to dabigatran ⓘ severe renal impairment ⓘ |
| hasDosageForm | oral capsule ⓘ |
| hasDrugInteraction |
P-glycoprotein inducers
ⓘ
P-glycoprotein inhibitors ⓘ |
| hasEffect |
reduces risk of stroke in atrial fibrillation
ⓘ
reduces risk of systemic embolism in atrial fibrillation ⓘ |
| hasEliminationHalfLife | approximately 12 to 17 hours ⓘ |
| hasIndication |
prevention of stroke in nonvalvular atrial fibrillation
ⓘ
prevention of systemic embolism in nonvalvular atrial fibrillation ⓘ reduction in risk of recurrence of deep vein thrombosis ⓘ reduction in risk of recurrence of pulmonary embolism ⓘ treatment of deep vein thrombosis ⓘ treatment of pulmonary embolism ⓘ venous thromboembolism prophylaxis after hip replacement surgery ⓘ |
| hasMajorRouteOfExcretion | renal ⓘ |
| hasMechanismOfAction | direct thrombin (factor IIa) inhibition ⓘ |
| hasPharmacologicClass |
DOAC
ⓘ
NOAC ⓘ direct oral anticoagulant ⓘ |
| hasPregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| hasProdrugForm |
dabigatran
self-linksurface differs
ⓘ
surface form:
dabigatran etexilate
|
| hasProteinBinding | approximately 35 percent ⓘ |
| hasReversalAgent | idarucizumab ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| inhibits |
factor IIa
ⓘ
thrombin ⓘ |
| isComparedWith | warfarin ⓘ |
| isConvertedTo | active dabigatran ⓘ |
| isEliminatedPrimarilyBy | kidney ⓘ |
| isReversedBy | idarucizumab ⓘ |
| isSubstrateOf | P-glycoprotein ⓘ |
| wasApprovedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: dabigatran Description of subject: Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Pradaxa
this entity surface form:
dabigatran etexilate